The Health Resources and Services Administration today launched a new website that organizations participating in the 340B Drug Pricing Program can use to determine the maximum prices drug companies can charge them for medications sold under the program.
“The AHA is pleased that, in response to our successful lawsuit, HRSA today launched a new website to shine needed light on 340B drug pricing, which the government has found lacking,” said AHA Executive Vice President Tom Nickels. “This website will help make sure hospitals participating in the program are not being overcharged by drug companies and that instances of price gouging can be uncovered and penalties enforced. As prescription drug prices continue to skyrocket, the 340B program is as crucial as ever in helping hospitals provide access to health care services for patients in vulnerable communities.”
HRSA last November issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems last September filed a lawsuit to force implementation of the rule.